Background Whether pre-existing glucose-lowering therapy influences outcomes after sepsis remains uncertain. We compared clinical outcomes among patients with type 2 diabetes (T2D) who developed sepsis according to prior GLP-1 receptor agonists (GLP-1RAs) or SGLT2 inhibitors (SGLT2is) use. Methods We conducted a retros...
Hao-Hsun Liu, Sheng-Chi Huang, Jheng-Yen Wu et al.· Drug Design, Development and...· 0 citations
Background The effect of sodium–glucose cotransporter-2 inhibitors (SGLT2i) in patients with left ventricular assist devices (LVAD) remains uncertain. We evaluated the association between SGLT2i use and adverse outcomes during the chronic post-LVAD phase. Methods We conducted a retrospective cohort study using the TriN...
Jheng-Yan Wu, Keng-Wei Lee, Sheng-Chi Huang et al.· Frontiers in Pharmacology· 0 citations
AIM
To evaluate whether the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) is associated with a reduced 1-year incidence of new-onset heart failure (HF) compared to statins among patients with dyslipidemia.
METHODS
We conducted a retrospective cohort study using the TriNetX global health re...
Jheng-Yan Wu, Keng-Wei Lee, Sheng-Chi Huang et al.· QJM : monthly journal of the...· 0 citations
In statin-treated patients with ASCVD, PCSK9i use was associated with a modestly lower 5-year incidence of new-onset AS, and this findings are hypothesis-generating.